Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.

Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS.

Nat Commun. 2012 Mar 6;3:724. doi: 10.1038/ncomms1727.

2.

Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma.

Rajakulendran T, Adam DN.

Int J Dermatol. 2014 Dec;53(12):1428-33. doi: 10.1111/ijd.12724. Epub 2014 Oct 14. Review.

PMID:
25311997
3.

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

Fedorenko IV, Paraiso KH, Smalley KS.

Biochem Pharmacol. 2011 Aug 1;82(3):201-9. doi: 10.1016/j.bcp.2011.05.015. Epub 2011 May 25. Review.

4.

A Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It.

Khan MA, El-Gamal MI, Oh CH.

Mini Rev Med Chem. 2017;17(4):351-365. Review.

PMID:
27337967
5.

Biological and therapeutic implications of the BRAF pathway in histiocytic disorders.

Arceci RJ.

Am Soc Clin Oncol Educ Book. 2014:e441-5. doi: 10.14694/EdBook_AM.2014.34.e441. Review.

6.

The evolution of melanoma resistance reveals therapeutic opportunities.

Das Thakur M, Stuart DD.

Cancer Res. 2013 Oct 15;73(20):6106-10. doi: 10.1158/0008-5472.CAN-13-1633. Epub 2013 Oct 4. Review.

7.

Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.

Mandal R, Becker S, Strebhardt K.

Oncogene. 2016 May 19;35(20):2547-61. doi: 10.1038/onc.2015.329. Epub 2015 Sep 14. Review.

PMID:
26364606

Supplemental Content

Support Center